CL2008000255A1 - Compuestos derivados de 2-aminooxazolinas; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de la depresion, ansiedad, trastorno bipolar, esquizofrenia, parkinson, alzheimer - Google Patents

Compuestos derivados de 2-aminooxazolinas; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de la depresion, ansiedad, trastorno bipolar, esquizofrenia, parkinson, alzheimer

Info

Publication number: CL2008000255A1
Authority: CL; Chile
Prior art keywords: compound; schizophrene; aminooxazolinas; anxiety; parkinson
Prior art date: 2007-02-02

Application number

CL200800255A

Other languages

English (en)

Inventor

Galley Katrin Groebke Zb Guido

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-02-02

Filing date

2008-01-30

Publication date

2008-08-08

2008-01-30 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2008-08-08 Publication of CL2008000255A1 publication Critical patent/CL2008000255A1/es

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/28—Nitrogen atoms not forming part of a nitro radical
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Diabetes (AREA)
Hematology (AREA)
Psychiatry (AREA)
Obesity (AREA)
Pain & Pain Management (AREA)
Epidemiology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Child & Adolescent Psychology (AREA)
Endocrinology (AREA)
Psychology (AREA)
Addiction (AREA)
Anesthesiology (AREA)
Hospice & Palliative Care (AREA)
Emergency Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

CL200800255A 2007-02-02 2008-01-30 Compuestos derivados de 2-aminooxazolinas; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de la depresion, ansiedad, trastorno bipolar, esquizofrenia, parkinson, alzheimer CL2008000255A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP07101681		2007-02-02

Publications (1)

Publication Number	Publication Date
CL2008000255A1 true CL2008000255A1 (es)	2008-08-08

Family

ID=39259491

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL200800255A CL2008000255A1 (es)	2007-02-02	2008-01-30	Compuestos derivados de 2-aminooxazolinas; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de la depresion, ansiedad, trastorno bipolar, esquizofrenia, parkinson, alzheimer

Country Status (24)

Country	Link
US (3)	US20080261920A1 (es)
EP (1)	EP2114906B1 (es)
JP (1)	JP5248528B2 (es)
KR (2)	KR101174191B1 (es)
CN (1)	CN101600700B (es)
AR (1)	AR065128A1 (es)
AU (1)	AU2008209860A1 (es)
BR (1)	BRPI0806940A2 (es)
CA (1)	CA2675221C (es)
CL (1)	CL2008000255A1 (es)
CO (1)	CO6321133A2 (es)
CR (1)	CR10926A (es)
EC (1)	ECSP099551A (es)
ES (1)	ES2510546T3 (es)
IL (1)	IL199783A0 (es)
MA (1)	MA31165B1 (es)
MX (1)	MX2009008255A (es)
NZ (1)	NZ578260A (es)
PE (1)	PE20081755A1 (es)
RU (1)	RU2473545C2 (es)
TW (1)	TW200838507A (es)
UA (1)	UA98951C2 (es)
WO (1)	WO2008092785A1 (es)
ZA (1)	ZA200905102B (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7700603B2 (en)	2003-12-15	2010-04-20	Schering Corporation	Heterocyclic aspartyl protease inhibitors
US7763609B2 (en)	2003-12-15	2010-07-27	Schering Corporation	Heterocyclic aspartyl protease inhibitors
US7592348B2 (en)	2003-12-15	2009-09-22	Schering Corporation	Heterocyclic aspartyl protease inhibitors
KR101335845B1 (ko) *	2007-02-15	2013-12-02	에프. 호프만-라 로슈 아게	Ｔａａｒ1 리간드로서의 2-아미노옥사졸린
JP5258904B2 (ja)	2008-02-18	2013-08-07	エフ．ホフマン−ラロシュアーゲー	４，５−ジヒドロオキサゾール−２−イルアミン誘導体
MX2011000464A (es) *	2008-07-24	2011-03-01	Hoffmann La Roche	Derivados de 4,5-dihidro-oxazol-2-ilo.
US8242153B2 (en)	2008-07-24	2012-08-14	Hoffmann-La Roche Inc.	4,5-dihydro-oxazol-2YL derivatives
BRPI0918449A2 (pt)	2008-09-11	2019-09-24	Amgen Inc	compostos de anel espiro-tricíclico como moduladores de beta-secretas e métodos de uso
US20100311798A1 (en) *	2009-06-05	2010-12-09	Decoret Guillaume	2-aminooxazolines as taar1 ligands
US8354441B2 (en)	2009-11-11	2013-01-15	Hoffmann-La Roche Inc.	Oxazoline derivatives
US9452980B2 (en)	2009-12-22	2016-09-27	Hoffmann-La Roche Inc.	Substituted benzamides
JP2013522305A (ja)	2010-03-15	2013-06-13	アムジエン・インコーポレーテツド	β−セクレターゼ調節剤としてのスピロ−四環式環化合物
US8497264B2 (en)	2010-03-15	2013-07-30	Amgen Inc.	Amino-oxazines and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
US9132136B2 (en) *	2010-08-02	2015-09-15	Hoffmann-La Roche Inc.	Pharmaceutical combination
WO2012019056A1 (en)	2010-08-05	2012-02-09	Amgen Inc.	Amino-iso-indole, amino-aza-iso-indole, amino-dihydroisoquinoline and amino-benzoxazine compounds as beta-secretase modulators and methods of use
US8673950B2 (en) *	2010-11-02	2014-03-18	Hoffmann-Laroche Inc.	Dihydrooxazol-2-amine derivatives
EP2643325A1 (en)	2010-11-23	2013-10-02	Amgen Inc.	Spiro-amino-imidazolone and spiro-amino-dihydro-pyrimidinone compounds as beta-secretase modulators and methods of use
EP2661307A4 (en)	2011-01-03	2014-08-06	Univ California	HIGH-DENSITY EPIDURAL STIMULATION TO FACILITATE MOVEMENTS, ATTACHMENTS, ARBITRARY MOVEMENTS AND RECOVERY OF AUTONOMIC, SEXUAL, VASOMOTORIC AND COGNITIVE FUNCTIONS AFTER NEUROLOGICAL INJURIES
US9346827B2 (en)	2011-02-07	2016-05-24	Amgen Inc.	5-amino-oxazepine and 5-amino-thiazepane compounds as beta secretase antagonists and methods of use
EP2675810A1 (en)	2011-02-15	2013-12-25	Amgen Inc.	Spiro-amino-imidazo-fused heterocyclic compounds as beta-secretase modulators and methods of use
EP2567959B1 (en)	2011-09-12	2014-04-16	Sanofi	6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US9296759B2 (en)	2011-09-21	2016-03-29	Amgen Inc.	Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
JP2014533183A (ja)	2011-11-11	2014-12-11	ニューロイネイブリングテクノロジーズインコーポレイテッド	運動神経、感覚、自律、性的、血管運動および認知機能の回復を可能にするための非侵襲性神経調節装置
US9725469B2 (en)	2012-11-15	2017-08-08	Amgen, Inc.	Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
UY35338A (es)	2013-02-21	2014-08-29	Bristol Myers Squibb Company Una Corporación Del Estado De Delaware	Compuestos bicíclicos moduladores de la actividad de s1p1 y composiciones farmacéuticas que los contienen
EP2821072A1 (en) *	2013-07-01	2015-01-07	Ecole Polytechnique Fédérale de Lausanne (EPFL)	Pharmacological stimulation to facilitate and restore standing and walking functions in spinal cord disorders
RS60825B1 (sr)	2016-03-17	2020-10-30	Hoffmann La Roche	Aktivnost derivata 5-etiol-4-metil-pirazol-3-karboksamida kao agonista taar-a
EP3452473A1 (en)	2016-05-04	2019-03-13	Purdue Pharma L.P.	Oxazoline pseudodimers, pharmaceutical compositions and the use thereof
EP3463359A4 (en) *	2016-06-02	2020-08-26	Purdue Pharma LP	SPURENAMINE-ASSOCIATED RECEPTOR-1 AGONISTS AND PARTIAL AGONISTS FOR PAIN MANAGEMENT
KR102233455B1 (ko)	2017-06-21	2021-03-29	주식회사 대웅제약	4-메톡시피롤 유도체의 중간체 제조 방법
CN107602381B (zh) *	2017-09-11	2021-03-16	陕西莱特光电材料股份有限公司	一种萘甲酸酯类衍生物及其制备方法
DE18205821T1 (de)	2018-11-13	2020-12-24	Gtx Medical B.V.	Steuerungssystem zur bewegungsrekonstruktion und/oder wiederherstellung für einen patienten
DE18205817T1 (de)	2018-11-13	2020-12-24	Gtx Medical B.V.	Sensor in bekleidung von gliedmassen oder schuhwerk
EP3695878B1 (en)	2019-02-12	2023-04-19	ONWARD Medical N.V.	A system for neuromodulation
WO2023235844A2 (en) *	2022-06-03	2023-12-07	Axsome Therapeutics	Carbamoyl phenylalaninol compounds as taar1 agonists
CN116903552A (zh) *	2023-06-07	2023-10-20	上海大学	一种手性α-氨基醇类化合物及其制备方法和应用

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2731471A (en) *		1956-01-17		Nxg hi
US2161938A (en) *	1934-07-31	1939-06-13	Soc Of Chemical Ind	Imidazolines
US2457047A (en) *	1946-02-13	1948-12-21	Monsanto Chemicals	2-(2'-thenyl)-4, 5-dihydroimidazoles and process for making the same
DE842065C (de)	1950-07-30	1952-06-23	Bayer Ag	Verfahren zur Herstellung stickstoffhaltiger heterocyclischer Verbindungen
US2778836A (en) *	1954-04-02	1957-01-22	Union Chimique Belge Sa	Substituted 2-methyl-delta2 imidazolines
US2744909A (en) *	1955-06-27	1956-05-08	Bristol Lab Inc	2-(ortho-phenylbenzyl) imidazoline and acid addition salts
US2744910A (en) *	1955-06-27	1956-05-08	Bristol Lab Inc	2-(ortho-benzylbenzyl)-imidazoline and acid addition salts
US2919274A (en) *	1957-09-17	1959-12-29	Sahyun Melville	Amidines
GB877306A (en)	1958-04-21	1961-09-13	Pfizer & Co C	Halogenated derivatives of tetrahydro-1-naphthyl cyclic amidines
DE1121054B (de) *	1960-11-23	1962-01-04	Merck Ag E	Verfahren zur Herstellung eines neuen Imidazolinderivates und dessen Saeureadditionssalzen
US3190802A (en)	1961-10-09	1965-06-22	Boehringer Sohn Ingelheim	Shaving composition and method of using same
FR1355049A (fr)	1962-04-12	1964-03-13	Merck Ag E	Agent pour le traitement préalable de la peau en vue du rasage
DE1150180B (de) *	1962-04-12	1963-06-12	Merck Ag E	Mittel zur Vorbehandlung der Haut fuer die Rasur
ES323985A1 (es)	1966-02-26	1966-12-16	Blade Pique Juan	Procedimiento para la obtenciën de derivados del imidazol
US3377247A (en) *	1967-04-28	1968-04-09	Dow Chemical Co	Antidepressant method
US3586695A (en) *	1968-01-26	1971-06-22	Dow Chemical Co	Substituted imidazolinyl indoles
US3577428A (en) *	1969-04-14	1971-05-04	Colgate Palmolive Co	2-amino-4-aryloxyalkyl-4-alkyl-2-oxazolines
BE754820R (fr) *	1969-08-13	1971-02-15	Schering Ag	Nouveaux derives de pyrimidine, leurs procedes de preparation et leurs
US3622579A (en) *	1969-08-28	1971-11-23	Boehringer Sohn Ingelheim	Derivatives of 2-anilino-1,3-diazacyclopentene-(2)
US3818094A (en) *	1969-08-28	1974-06-18	Boehringer Sohn Ingelheim	Hypotensive pharmaceutical compositions containing certain 2-anilino-1,3-diazacyclopentenes-(2)
US3660423A (en) *	1970-02-13	1972-05-02	Dow Chemical Co	2-(substituted benzyl)methyl-2-imidazolines
GB1333471A (en)	1971-01-27	1973-10-10	Labaz	Imidazoline derivatives and process for preparing the same
DE2253555A1 (de)	1972-11-02	1974-05-09	Hoechst Ag	Oxazolo-pyrimidine und verfahren zu ihrer herstellung
US4125620A (en) *	1974-10-01	1978-11-14	Boehringer Ingelheim Gmbh	2-[(2',6'-Disubstituted-phenyl)-imino]-imidazolidines and salts thereof
DE2446758C3 (de)	1974-10-01	1979-01-04	C.H. Boehringer Sohn, 6507 Ingelheim	2-(2-Fluor-6-trifluormethylphenylimino)-imidazolidin, dessen Säureadditionssalze, Verfahren zur Herstellung dieser Verbindungen und deren Verwendung bei der Bekämpfung der Hypertonie
US3992403A (en) *	1975-05-30	1976-11-16	Schering Corporation	2-Imidazolines and their use as hypoglycemic agents
GB1538097A (en) *	1976-01-26	1979-01-10	Lafon Labor	Substituted phenyl-amidines
US4323570A (en) *	1978-11-15	1982-04-06	Beiersdorf Aktiengesellschaft	Substituted aminopyrimidines
DE2849537C2 (de)	1978-11-15	1983-03-17	Beiersdorf Ag, 2000 Hamburg	Substituierte 5-(2-Imidazolin-2-yl)-aminopyrimidine, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
SE431818C (sv) *	1979-03-16	1985-04-29	Turos Foodprocessing Ab	Forfarande for framstellning av crumbprodukter genom blandning av floden av mjolkravara, proteiner och reducerande socker
AU518569B2 (en)	1979-08-07	1981-10-08	Farmos-Yhtyma Oy	4-benzyl- and 4-benzoyl imidazole derivatives
US4311840A (en) *	1980-11-13	1982-01-19	E. R. Squibb & Sons, Inc.	2,3,6,7-Tetrahydro-2-thioxo-4H-oxazolo[3,2-a]-1,3,5 triazin-4-ones
US4540705A (en)	1983-03-14	1985-09-10	Sterling Drug Inc.	Antidepressant imidazolines and related compounds
EP0166937B1 (en)	1984-06-06	1991-08-28	Abbott Laboratories	Adrenergic compounds
DK302185A (da) *	1984-07-05	1986-01-06	Rolland Sa A	2-amino-oxazoliner samt fremgangsmaade til deres fremstilling
US4665095A (en) *	1985-12-11	1987-05-12	Abbott Laboratories	Use of 2-[(3,5-dihalo-4-aminobenzyl)]imidazolines to stimulate alpha-1 adrenergic receptors and to treat nasal congestion
GB2215206B (en)	1988-02-29	1991-07-03	Farmos Oy	4-substituted imidazole derivatives useful in perioperative care
FR2645860B1 (fr) *	1989-04-14	1991-07-26	Sarget Lab	Nouvelles aryloxymethyl-5 amino-2 oxazolines, syntheses et applications therapeutiques
FI894911A0 (fi)	1989-10-17	1989-10-17	Farmos Oy	En terapeutiskt vaerdefull foerening.
CA2211325C (en)	1993-10-13	2006-08-15	H. Joseph Horacek	Extended release clonidine formulation
GB9425211D0 (en)	1994-12-14	1995-02-15	Ucb Sa	Substituted 1H-imidazoles
DE19514579A1 (de) *	1995-04-20	1996-10-24	Boehringer Ingelheim Kg	Verwendung von alpha¶1¶¶L¶-Agonisten zur Behandlung der Harninkontinenz
US5610174A (en) *	1995-06-02	1997-03-11	Synaptic Pharmaceutical Corporation	Use of α1A -selective adrenoceptor agonists for the treatment of urinary incontinence
GB9520150D0 (en)	1995-10-03	1995-12-06	Orion Yhtymae Oy	New imidazole derivatives
US5969137A (en)	1996-09-19	1999-10-19	Virginia Commonwealth University	Benzylamidine derivatives with serotonin receptor binding activity
IL123232A0 (en)	1997-02-11	1999-11-30	Lilly Co Eli	Medicament for inhibiting glucose metabolism deterioration
US5866579A (en) *	1997-04-11	1999-02-02	Synaptic Pharmaceutical Corporation	Imidazole and imidazoline derivatives and uses thereof
US6841684B2 (en)	1997-12-04	2005-01-11	Allergan, Inc.	Imidiazoles having reduced side effects
SK8542000A3 (en)	1997-12-04	2001-03-12	Allergan Sales Inc	Substituted imidazole derivatives having agonist-like activity at alpha 2b or 2b/2c adrenergic receptors
AU2003099A (en)	1997-12-19	1999-07-12	Eli Lilly And Company	Method for treating diabetes
ATE293102T1 (de) *	1998-04-23	2005-04-15	Takeda Pharmaceutical	Naphthalene derivate ,ihre herstellung und verwendung
ES2150378B1 (es)	1998-08-07	2001-07-01	Esteve Labor Dr	Empleo de derivados de aril(o heteroaril)azolilcarbinoles en la elaboracion de un medicamento para el tratamiento de los trastornos mediados por un exceso de substancia p.
CA2246027A1 (en)	1998-08-27	2000-02-27	Virginia Commonwealth University	Benzylamidine derivatives with serotonin receptor binding activity
DE19858593A1 (de) *	1998-12-18	2000-06-21	Merck Patent Gmbh	Sulfonyloxazolamine als therapeutische Wirkstoffe
PE20010781A1 (es)	1999-10-22	2001-08-08	Takeda Chemical Industries Ltd	Compuestos 1-(1h-imidazol-4-il)-1-(naftil-2-sustituido)etanol, su produccion y utilizacion
JP2001302643A (ja)	2000-04-21	2001-10-31	Suntory Ltd	環状アミジン化合物
EP1319070A2 (en)	2000-09-12	2003-06-18	Oregon Health & Science University	Mammalian receptor genes and uses
SK7222003A3 (en)	2000-11-14	2004-05-04	Hoffmann La Roche	Substituted 2-phenylaminoimidazoline phenyl ketone derivatives as IP antagonists
IL147921A0 (en) *	2002-01-31	2002-08-14	Abdulrazik Mohammad	A method for treating central nervous system disorders by ocular dosing
TW200306783A (en)	2002-04-29	2003-12-01	Fmc Corp	Pesticidal heterocycles
KR100492252B1 (ko)	2002-08-09	2005-05-30	한국화학연구원	이미다졸을 포함하는 이차아민으로 치환된 벤조피란유도체 및 그의 제조방법
BRPI0610195A2 (pt)	2005-05-03	2010-06-01	Bayer Cropscience Ag	derivados inseticidas de aminoalquil heterociclila e heteroarila substituìdas
PE20070336A1 (es)	2005-08-25	2007-04-16	Schering Corp	Compuestos de indolina como agonistas de receptores adrenergicos alfa2c funcionalmente selectivos
JP2009524617A (ja)	2006-01-27	2009-07-02	エフ．ホフマン−ラロシュアーゲー	置換２−イミダゾール又はイミダゾリン誘導体の使用
CN101374832B (zh)	2006-01-27	2013-03-06	弗·哈夫曼-拉罗切有限公司	4-咪唑衍生物用于cns病症的用途

2008
- 2008-01-23 KR KR1020097018315A patent/KR101174191B1/ko not_active Expired - Fee Related
- 2008-01-23 WO PCT/EP2008/050765 patent/WO2008092785A1/en active Application Filing
- 2008-01-23 CA CA2675221A patent/CA2675221C/en not_active Expired - Fee Related
- 2008-01-23 RU RU2009128619/04A patent/RU2473545C2/ru not_active IP Right Cessation
- 2008-01-23 AU AU2008209860A patent/AU2008209860A1/en not_active Abandoned
- 2008-01-23 BR BRPI0806940-9A2A patent/BRPI0806940A2/pt not_active Application Discontinuation
- 2008-01-23 MX MX2009008255A patent/MX2009008255A/es active IP Right Grant
- 2008-01-23 JP JP2009547642A patent/JP5248528B2/ja not_active Expired - Fee Related
- 2008-01-23 CN CN2008800039235A patent/CN101600700B/zh not_active Expired - Fee Related
- 2008-01-23 ES ES08701646.5T patent/ES2510546T3/es active Active
- 2008-01-23 NZ NZ578260A patent/NZ578260A/en not_active IP Right Cessation
- 2008-01-23 EP EP08701646.5A patent/EP2114906B1/en active Active
- 2008-01-23 KR KR1020127008523A patent/KR101275405B1/ko not_active Expired - Fee Related
- 2008-01-23 UA UAA200908758A patent/UA98951C2/ru unknown
- 2008-01-25 US US12/011,384 patent/US20080261920A1/en not_active Abandoned
- 2008-01-30 TW TW097103520A patent/TW200838507A/zh unknown
- 2008-01-30 CL CL200800255A patent/CL2008000255A1/es unknown
- 2008-01-31 PE PE2008000228A patent/PE20081755A1/es not_active Application Discontinuation
- 2008-02-01 AR ARP080100418A patent/AR065128A1/es unknown
2009
- 2009-07-09 IL IL199783A patent/IL199783A0/en unknown
- 2009-07-13 CO CO09072375A patent/CO6321133A2/es not_active Application Discontinuation
- 2009-07-14 CR CR10926A patent/CR10926A/es unknown
- 2009-07-21 ZA ZA200905102A patent/ZA200905102B/xx unknown
- 2009-07-31 EC EC2009009551A patent/ECSP099551A/es unknown
- 2009-08-04 MA MA32143A patent/MA31165B1/fr unknown
- 2009-12-16 US US12/639,076 patent/US20100120864A1/en not_active Abandoned
2012
- 2012-03-22 US US13/426,736 patent/US8604061B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
BRPI0806940A2 (pt)	2014-05-06
AR065128A1 (es)	2009-05-20
US20120196903A1 (en)	2012-08-02
CN101600700A (zh)	2009-12-09
KR20090106655A (ko)	2009-10-09
KR20120045066A (ko)	2012-05-08
ES2510546T3 (es)	2014-10-21
JP2010517953A (ja)	2010-05-27
JP5248528B2 (ja)	2013-07-31
MX2009008255A (es)	2009-08-12
EP2114906B1 (en)	2014-08-06
IL199783A0 (en)	2010-04-15
RU2009128619A (ru)	2011-03-10
ECSP099551A (es)	2009-08-28
CN101600700B (zh)	2013-08-21
PE20081755A1 (es)	2008-12-06
CA2675221C (en)	2016-02-23
NZ578260A (en)	2012-02-24
US20080261920A1 (en)	2008-10-23
UA98951C2 (ru)	2012-07-10
ZA200905102B (en)	2010-05-26
RU2473545C2 (ru)	2013-01-27
KR101174191B1 (ko)	2012-08-14
US8604061B2 (en)	2013-12-10
CR10926A (es)	2009-08-12
TW200838507A (en)	2008-10-01
CO6321133A2 (es)	2011-09-20
US20100120864A1 (en)	2010-05-13
CA2675221A1 (en)	2008-08-07
KR101275405B1 (ko)	2013-06-17
AU2008209860A1 (en)	2008-08-07
WO2008092785A1 (en)	2008-08-07
EP2114906A1 (en)	2009-11-11
MA31165B1 (fr)	2010-02-01

Publication	Publication Date	Title
CL2008000255A1 (es)	2008-08-08	Compuestos derivados de 2-aminooxazolinas; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de la depresion, ansiedad, trastorno bipolar, esquizofrenia, parkinson, alzheimer
CL2008003593A1 (es)	2010-01-04	Compuestos derivados de isoxazolo-piridazina; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de trastornos cognitivos como el alzheimer
CL2007001042A1 (es)	2008-02-08	Compuestos derivados de tioxantina; composicion farmaceutica que comprende a dicho compuesto; y uso en el tratamiento de desordenes neuroinflamatorios como esclerosis multiple, parkinson, en desordenes ateroscleroticos, cardio- y cerebrovascular, des
CL2007002121A1 (es)	2008-02-22	Compuestos derivados de pirazoles, activadores de glucoquinasa; proceso de preparacion de dichos compuestos; composicion farmaceutica que comprende dichos compuestos; y uso para el tratamiento de enfermedades y/o trastornos metabolicos, tal como diab
CL2007003614A1 (es)	2008-06-20	Compuestos derivados de sulfonil-fenil-2h-[1,2,4]oxadiazol-5-ona; composicion farmaceutica que comprende a dicho compuesto; procedimiento de preparacion; y uso del compuesto en el tratamiento de trastornos del metabolismo, como diabetes mellitus, dis
CL2009000349A1 (es)	2010-02-19	Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
CL2007001830A1 (es)	2008-04-04	Compuestos derivados de isoindol; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de deterioro cognitivo, alzheimer, neurodegeneracion y demencia.
CL2015000331A1 (es)	2015-08-28	Compuestos derivados de piridazina 1,4-disustitutidos; composicion y combinacion farmaceutica que los comprende y uso en el tratamiento de la atrofia muscular espinal.
CL2008000434A1 (es)	2008-08-22	Compuestos derivados de 2-amino-oxazolinas; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como depresion, ansiedad, estres, trastorno bipolar, entre otros.
CL2007003202A1 (es)	2008-03-07	Compuestos derivados de espiroindolinona; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos de proliferacion celular.
CL2007002996A1 (es)	2008-06-13	Compuestos derivados de quinolina sustituido, moduladores de los receptores x del higado; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como sindrome coronario agudo, alzheimer, diabetes y aterosclerosis.
CL2008000531A1 (es)	2008-09-22	Compuestos derivados de heterociclos, inhibidores de la aspartilproteasa; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de enfermedades cardiovasculares, cognitivas y neurodegenerativas tales como la enfermeda
CL2008001721A1 (es)	2008-12-19	Compuestos derivados de 17-beta-ciano-18 alfa-homo-19-nor-androst-4-eno; que presentan actividad gestagena y antimineralcorticoide; composicion farmaceutica; y uso en el tratamiento de trastornos pre-peri-y posmenopausicos y trastornos premenstruales.
CR20110100A (es)	2011-07-06	Nuevos derivados de sulfamida sustituida
CL2009000860A1 (es)	2010-05-07	Compuestos derivados de 4-fenil-4-metil-5,6-dihidro-4h-1,3-tiazina-2-amina; composiciones farmaceuticas que los contienen; y uso de los compuestos en la preparacion de medicamentos inhibidores de bace, utiles para el tratamiento de trastornos mediados por esta enzima, tal como la enfermedad de alzheimer.
CL2007003033A1 (es)	2008-05-16	Compuestos derivados de benzoilamino heterociclos; procedimiento de preparacion; composicion farmaceutica que lo comprende; y uso del compuesto en el tratamiento de la diabetes tipo ii.
CL2007002234A1 (es)	2008-06-13	Compuestos derivados de heterociclos de nitrogeno; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de enfermedades proliferativas.
CL2009000119A1 (es)	2010-03-05	Compuestos derivados de amino-bencimidazoles sustituidos; composicion farmaceutica; y su uso en el tratamiento del alzheimer.
DK2303330T4 (da)	2021-09-13	Farmaceutiske sammensætninger til behandling af parkinsons sygdom
CL2008002369A1 (es)	2009-07-17	Compuestos derivados de piridin-3-il-oxipiridin-2-il-amino, inhibidores de alk5; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento del cancer.
CL2008001123A1 (es)	2009-01-02	Compuestos derivados de acido lipoico; formulacion farmaceutica que lo comprende; y uso en el tratamiento del cancer.
CL2008002049A1 (es)	2009-01-23	Compuestos derivados de aminoindol macrociclicos; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c.
CL2008002809A1 (es)	2009-11-27	Compuestos derivados de cianoisoquinolina; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una adiccion a las drogas, en el tratamiento de un trastorno neurodegenerativo, como alzheimer, parkinson, demencia, entre otros.
CL2008000254A1 (es)	2008-08-08	Compuestos derivados de 6-oxo-6,7-dihidro-5h-dibenzo-[b,d]azepin-7-ilo; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de la enfermedad de alzheimer o cancer.
CL2008000304A1 (es)	2008-08-08	Compuestos derivados de 1-oxa-3-azaespiro[4.5]decan-2-ona; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de un trastorno de la alimentacion, obesidad, depresion.